nafronyl has been researched along with Central Nervous System Diseases in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wallerstein, PV | 1 |
| Licht, B | 1 |
| Kronenwerth, D | 1 |
1 trial available for nafronyl and Central Nervous System Diseases
| Article | Year |
|---|---|
[Reflections on the therapy of geriatric diseases of the central nervous system].
Topics: Age Factors; Aged; Central Nervous System Diseases; Drug Evaluation; Humans; Middle Aged; Nafronyl; | 1975 |